{
  "E138A": {
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A."
  },
  "E138A,G140A,Q148R": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility."
  },
  "E138A,G140S,Q148H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility."
  },
  "E138A,G140S,Q148H,E157Q": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little, if any, effect on INSTI susceptibility."
  },
  "E138A,G140S,Y143H,Q148H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN143H": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Y143H is a less-common mutation at this position that is likely a transitional mutation between the wildtype Y amino acid and the mutant R (which differs from the wildtype Y by two nucleotides).",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility."
  },
  "E138A,Q148H": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility."
  },
  "E138A,S147G,Q148R,N155H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN147G": "S147G is a non-polymorphic mutation selected in patients receiving EVG. It moderately reduces EVG susceptibility (5-10-fold). It does not reduce RAL or DTGsusceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility."
  },
  "E138K": {
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A."
  },
  "E138K,G140A,Q148K": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility."
  },
  "E138K,G140A,Q148K,N155H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility."
  },
  "E138K,G140A,Q148R,N155H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility."
  },
  "E138K,G140C,Q148R": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility."
  },
  "E138K,G140S,Q148H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility."
  },
  "E138K,G140S,Q148R": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility."
  },
  "E138K,G140S,Q148R,G163R": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "E138K,G140S,S147G,Q148R": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN147G": "S147G is a non-polymorphic mutation selected in patients receiving EVG. It moderately reduces EVG susceptibility (5-10-fold). It does not reduce RAL or DTGsusceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility."
  },
  "E138K,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility."
  },
  "E138K,Q148R,N155H,G163K": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "E138K,S147G,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN147G": "S147G is a non-polymorphic mutation selected in patients receiving EVG. It moderately reduces EVG susceptibility (5-10-fold). It does not reduce RAL or DTGsusceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility."
  },
  "E138K,S147G,Q148R,G163R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN147G": "S147G is a non-polymorphic mutation selected in patients receiving EVG. It moderately reduces EVG susceptibility (5-10-fold). It does not reduce RAL or DTGsusceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "E138K,Y143C,N155H,G163R,S230R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL, EVG, and rarely DTG. It appears to have minimal, if any, effect on INSTI susceptibility."
  },
  "E138K,Y143R,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility."
  },
  "E138T": {
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A."
  },
  "E138T,G140S,Q148H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility."
  },
  "E157Q": {
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little, if any, effect on INSTI susceptibility."
  },
  "E157Q,G163R": {
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "E157Q,R263K": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN263K": "R263K is an uncommon mutation selected in patients receiving RAL and DTG and in vitro by EVG, DTG, and BIC. It reduces EVG susceptibility by about 4-fold, and RAL, DTG, and BIC susceptibility by about 2-fold."
  },
  "E92G": {
    "IN92G": "E92G is a rare non-polymorphic mutation that has been selected in patients receiving EVG. It moderately reduces EVG susceptibility but does not reduce RAL or DTG susceptibility."
  },
  "E92G,N155H": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN92G": "E92G is a rare non-polymorphic mutation that has been selected in patients receiving EVG. It moderately reduces EVG susceptibility but does not reduce RAL or DTG susceptibility."
  },
  "E92G,T97A,N155H,G163R": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN92G": "E92G is a rare non-polymorphic mutation that has been selected in patients receiving EVG. It moderately reduces EVG susceptibility but does not reduce RAL or DTG susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "E92Q": {
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate and high-level reductions in RAL and EVG susceptibility, respectively. It is selected in vitro by DTG and reduces DTG susceptibility \u003c\u003d1.5-fold. Its effect on BIC is uncertain."
  },
  "E92Q,E138K,N155H": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate and high-level reductions in RAL and EVG susceptibility, respectively. It is selected in vitro by DTG and reduces DTG susceptibility \u003c\u003d1.5-fold. Its effect on BIC is uncertain."
  },
  "E92Q,E138K,Y143C,N155H,S230R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL, EVG, and rarely DTG. It appears to have minimal, if any, effect on INSTI susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate and high-level reductions in RAL and EVG susceptibility, respectively. It is selected in vitro by DTG and reduces DTG susceptibility \u003c\u003d1.5-fold. Its effect on BIC is uncertain."
  },
  "E92Q,G140S,Q148K,N155H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate and high-level reductions in RAL and EVG susceptibility, respectively. It is selected in vitro by DTG and reduces DTG susceptibility \u003c\u003d1.5-fold. Its effect on BIC is uncertain."
  },
  "E92Q,G140S,Q148R,N155H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate and high-level reductions in RAL and EVG susceptibility, respectively. It is selected in vitro by DTG and reduces DTG susceptibility \u003c\u003d1.5-fold. Its effect on BIC is uncertain."
  },
  "E92Q,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate and high-level reductions in RAL and EVG susceptibility, respectively. It is selected in vitro by DTG and reduces DTG susceptibility \u003c\u003d1.5-fold. Its effect on BIC is uncertain."
  },
  "E92Q,N155H,E157Q": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate and high-level reductions in RAL and EVG susceptibility, respectively. It is selected in vitro by DTG and reduces DTG susceptibility \u003c\u003d1.5-fold. Its effect on BIC is uncertain."
  },
  "E92Q,N155H,G163R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate and high-level reductions in RAL and EVG susceptibility, respectively. It is selected in vitro by DTG and reduces DTG susceptibility \u003c\u003d1.5-fold. Its effect on BIC is uncertain."
  },
  "E92Q,Q95K,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate and high-level reductions in RAL and EVG susceptibility, respectively. It is selected in vitro by DTG and reduces DTG susceptibility \u003c\u003d1.5-fold. Its effect on BIC is uncertain.",
    "IN95K": "Q95K is a non-polymorphic accessory mutation selected in patients receiving RAL and in vitro by EVG. Alone, it has little if any effect on INSTI susceptibility."
  },
  "E92Q,T97A": {
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate and high-level reductions in RAL and EVG susceptibility, respectively. It is selected in vitro by DTG and reduces DTG susceptibility \u003c\u003d1.5-fold. Its effect on BIC is uncertain.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "E92Q,T97A,E157Q": {
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate and high-level reductions in RAL and EVG susceptibility, respectively. It is selected in vitro by DTG and reduces DTG susceptibility \u003c\u003d1.5-fold. Its effect on BIC is uncertain.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "E92Q,T97A,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate and high-level reductions in RAL and EVG susceptibility, respectively. It is selected in vitro by DTG and reduces DTG susceptibility \u003c\u003d1.5-fold. Its effect on BIC is uncertain.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "E92Q,T97A,Y143H,N155H": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143H": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Y143H is a less-common mutation at this position that is likely a transitional mutation between the wildtype Y amino acid and the mutant R (which differs from the wildtype Y by two nucleotides).",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate and high-level reductions in RAL and EVG susceptibility, respectively. It is selected in vitro by DTG and reduces DTG susceptibility \u003c\u003d1.5-fold. Its effect on BIC is uncertain.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "E92Q,T97A,Y143R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate and high-level reductions in RAL and EVG susceptibility, respectively. It is selected in vitro by DTG and reduces DTG susceptibility \u003c\u003d1.5-fold. Its effect on BIC is uncertain.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "E92Q,Y143H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143H": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Y143H is a less-common mutation at this position that is likely a transitional mutation between the wildtype Y amino acid and the mutant R (which differs from the wildtype Y by two nucleotides).",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate and high-level reductions in RAL and EVG susceptibility, respectively. It is selected in vitro by DTG and reduces DTG susceptibility \u003c\u003d1.5-fold. Its effect on BIC is uncertain."
  },
  "E92V,N155H": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN92V": "E92V is a rare non-polymorphic mutation selected in vitro by an investigational INSTI. It causes intermediate and high-level reductionss in EVG and RAL susceptibility, respectively."
  },
  "F121Y": {
    "IN121Y": "F121Y is a non-polymorphic mutation selected in vitro by RAL and EVG. It has been reported rarely in patients receiving RAL. It reduces susceptibility to RAL by ~10-fold and to EVG by ~30-fold."
  },
  "F121Y,N155H,G163R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN121Y": "F121Y is a non-polymorphic mutation selected in vitro by RAL and EVG. It has been reported rarely in patients receiving RAL. It reduces susceptibility to RAL by ~10-fold and to EVG by ~30-fold.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140A,Q148K": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility."
  },
  "G140A,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility."
  },
  "G140A,Q148R,E157Q": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little, if any, effect on INSTI susceptibility."
  },
  "G140A,Q148R,G163K": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140A,Q148R,G163R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140S": {
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility."
  },
  "G140S,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility."
  },
  "G140S,Q148H": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility."
  },
  "G140S,Q148H,E157Q": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little, if any, effect on INSTI susceptibility."
  },
  "G140S,Q148H,E157Q,G163K": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140S,Q148H,G163K": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140S,Q148H,G163R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140S,Q148H,N155H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility."
  },
  "G140S,Q148H,N155H,E157Q": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little, if any, effect on INSTI susceptibility."
  },
  "G140S,Q148H,V151A": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN151A": "V151A is an extremely rare non-polymorphic mutation selected in vitro by an investigational INSTI. It is associated with minimally reduced susceptibility to RAL and EVG."
  },
  "G140S,Q148K,N155H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility."
  },
  "G140S,Q148K,N155H,G163R": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140S,Q148N": {
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148N": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility. Q148N is a rare INSTI-selected mutation that causes ~3-fold reduced EVG susceptibility and may represent a reversion from Q148H or Q148K."
  },
  "G140S,Q148N,G163R": {
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148N": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility. Q148N is a rare INSTI-selected mutation that causes ~3-fold reduced EVG susceptibility and may represent a reversion from Q148H or Q148K.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140S,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility."
  },
  "G140S,Q148R,G163K": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140S,Q148R,G163R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140S,Q148R,N155H,E157Q": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little, if any, effect on INSTI susceptibility."
  },
  "G140S,Y143H,Q148H": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN143H": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Y143H is a less-common mutation at this position that is likely a transitional mutation between the wildtype Y amino acid and the mutant R (which differs from the wildtype Y by two nucleotides).",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility."
  },
  "G140S,Y143H,Q148H,G163R": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN143H": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Y143H is a less-common mutation at this position that is likely a transitional mutation between the wildtype Y amino acid and the mutant R (which differs from the wildtype Y by two nucleotides).",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140S,Y143R,Q148H": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility."
  },
  "G163K": {
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G163R": {
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "H51Y": {
    "IN51Y": "H51Y is a rare non-polymorphic accessory mutation selected in patients receiving RAL and EVG and in vitro by DTG. H51Y minimally reduces EVG susceptibility (~2 to 3-fold). It does not reduce RAL or DTG susceptibility."
  },
  "H51Y,E92Q,G140S,Q148K,N155H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN51Y": "H51Y is a rare non-polymorphic accessory mutation selected in patients receiving RAL and EVG and in vitro by DTG. H51Y minimally reduces EVG susceptibility (~2 to 3-fold). It does not reduce RAL or DTG susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate and high-level reductions in RAL and EVG susceptibility, respectively. It is selected in vitro by DTG and reduces DTG susceptibility \u003c\u003d1.5-fold. Its effect on BIC is uncertain."
  },
  "H51Y,E92Q,G140S,Q148K,N155H,G163R": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN51Y": "H51Y is a rare non-polymorphic accessory mutation selected in patients receiving RAL and EVG and in vitro by DTG. H51Y minimally reduces EVG susceptibility (~2 to 3-fold). It does not reduce RAL or DTG susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate and high-level reductions in RAL and EVG susceptibility, respectively. It is selected in vitro by DTG and reduces DTG susceptibility \u003c\u003d1.5-fold. Its effect on BIC is uncertain."
  },
  "H51Y,G140S,Q148K": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN51Y": "H51Y is a rare non-polymorphic accessory mutation selected in patients receiving RAL and EVG and in vitro by DTG. H51Y minimally reduces EVG susceptibility (~2 to 3-fold). It does not reduce RAL or DTG susceptibility."
  },
  "H51Y,T66A,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN51Y": "H51Y is a rare non-polymorphic accessory mutation selected in patients receiving RAL and EVG and in vitro by DTG. H51Y minimally reduces EVG susceptibility (~2 to 3-fold). It does not reduce RAL or DTG susceptibility.",
    "IN66A": "T66A is a non-polymorphic mutation selected in patients receiving EVG and RAL, usually in combination with other INSTI-resistance mutations. It causes a moderatereduction in EVG susceptibility (~5-fold). It does not appear to reduce RAL or DTG susceptibility."
  },
  "L74I,E138K,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74I,E138K,S147G,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN147G": "S147G is a non-polymorphic mutation selected in patients receiving EVG. It moderately reduces EVG susceptibility (5-10-fold). It does not reduce RAL or DTGsusceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74I,E138K,S147G,Q148R,G163R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN147G": "S147G is a non-polymorphic mutation selected in patients receiving EVG. It moderately reduces EVG susceptibility (5-10-fold). It does not reduce RAL or DTGsusceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74I,E138T,G140S,Q148H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74I,G140S,Q148H": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74I,G140S,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74I,G140S,Q148R,E157Q": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74I,G140S,Q148R,G163R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74I,G140S,Q148R,R263K": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN263K": "R263K is an uncommon mutation selected in patients receiving RAL and DTG and in vitro by EVG, DTG, and BIC. It reduces EVG susceptibility by about 4-fold, and RAL, DTG, and BIC susceptibility by about 2-fold.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74I,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74I,T97A,Y143C,S230R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL, EVG, and rarely DTG. It appears to have minimal, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74I,T97A,Y143G": {
    "IN143KGSA": "Y143K/G/S/A are rare mutations that cause intermediate reductions in RAL susceptibility. When they occur in combination with other accessory mutations, they may also cause low-level reductions in EVG susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74I,T97A,Y143R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74I,T97A,Y143R,E157Q": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74I,T97A,Y143S": {
    "IN143KGSA": "Y143K/G/S/A are rare mutations that cause intermediate reductions in RAL susceptibility. When they occur in combination with other accessory mutations, they may also cause low-level reductions in EVG susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74I,Y143R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74M,E138K,G140C,Q148R,E157Q": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74M,E138T,G140S,Q148H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74M,E92Q,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate and high-level reductions in RAL and EVG susceptibility, respectively. It is selected in vitro by DTG and reduces DTG susceptibility \u003c\u003d1.5-fold. Its effect on BIC is uncertain."
  },
  "L74M,G140A,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74M,G140C,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74M,G140C,Q148R,G163R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74M,G140S,Q148H": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74M,G140S,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74M,G140S,Q148R,E157Q": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74M,Q95K,T97A,Y143C,S230R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL, EVG, and rarely DTG. It appears to have minimal, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN95K": "Q95K is a non-polymorphic accessory mutation selected in patients receiving RAL and in vitro by EVG. Alone, it has little if any effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74M,Q95K,T97A,Y143R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN95K": "Q95K is a non-polymorphic accessory mutation selected in patients receiving RAL and in vitro by EVG. Alone, it has little if any effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74M,Q95K,Y143C,S230R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL, EVG, and rarely DTG. It appears to have minimal, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN95K": "Q95K is a non-polymorphic accessory mutation selected in patients receiving RAL and in vitro by EVG. Alone, it has little if any effect on INSTI susceptibility."
  },
  "L74M,T97A,E138A,Y143C": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74M,T97A,E138K,Y143C,S230R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL, EVG, and rarely DTG. It appears to have minimal, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74M,T97A,E138K,Y143R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74M,T97A,Y143C,G163R,S230R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL, EVG, and rarely DTG. It appears to have minimal, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74M,T97A,Y143C,S230R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL, EVG, and rarely DTG. It appears to have minimal, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74M,T97A,Y143G": {
    "IN143KGSA": "Y143K/G/S/A are rare mutations that cause intermediate reductions in RAL susceptibility. When they occur in combination with other accessory mutations, they may also cause low-level reductions in EVG susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74M,T97A,Y143G,G163R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143KGSA": "Y143K/G/S/A are rare mutations that cause intermediate reductions in RAL susceptibility. When they occur in combination with other accessory mutations, they may also cause low-level reductions in EVG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74M,T97A,Y143H,G163R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143H": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Y143H is a less-common mutation at this position that is likely a transitional mutation between the wildtype Y amino acid and the mutant R (which differs from the wildtype Y by two nucleotides).",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74M,T97A,Y143R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74M,T97A,Y143R,E157Q": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74M,T97A,Y143R,G163K": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74M,T97A,Y143S,S230R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143KGSA": "Y143K/G/S/A are rare mutations that cause intermediate reductions in RAL susceptibility. When they occur in combination with other accessory mutations, they may also cause low-level reductions in EVG susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL, EVG, and rarely DTG. It appears to have minimal, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74M,Y143C": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74M,Y143C,N155H,S230R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL, EVG, and rarely DTG. It appears to have minimal, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74M,Y143R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "L74M,Y143R,E157Q": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "N155H": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility."
  },
  "N155H,E157Q": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little, if any, effect on INSTI susceptibility."
  },
  "N155H,E157Q,G163K": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "N155H,E157Q,G163R": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "N155H,G163K": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "N155H,G163R": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "N155H,R263K": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN263K": "R263K is an uncommon mutation selected in patients receiving RAL and DTG and in vitro by EVG, DTG, and BIC. It reduces EVG susceptibility by about 4-fold, and RAL, DTG, and BIC susceptibility by about 2-fold."
  },
  "N155H,S230R": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL, EVG, and rarely DTG. It appears to have minimal, if any, effect on INSTI susceptibility."
  },
  "N155T": {
    "IN155ST": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility. N155S/T are extremely rare non-polymorphic mutations selected in vitro by investigational INSTIs. They reduce RAL and EVG susceptibility somewhat less than does N155H."
  },
  "P145S": {
    "IN145S": "P145S is a rare non-polymorphic mutation selected in vitro by EVG and rarely in patients receiving EVG. It causes high-level resistance to EVG but not to RAL or DTG."
  },
  "Q146P": {
    "IN146P": "Q146P is a rare non-polymorphic mutation selected in vitro by EVG. It causes intermediate to high-level reductions in EVG susceptibility (~5 to 10-fold)."
  },
  "Q148H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility."
  },
  "Q148R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility."
  },
  "Q148R,E157Q": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little, if any, effect on INSTI susceptibility."
  },
  "Q148R,N155H": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility."
  },
  "Q95K": {
    "IN95K": "Q95K is a non-polymorphic accessory mutation selected in patients receiving RAL and in vitro by EVG. Alone, it has little if any effect on INSTI susceptibility."
  },
  "Q95K,E138K,S147G,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN147G": "S147G is a non-polymorphic mutation selected in patients receiving EVG. It moderately reduces EVG susceptibility (5-10-fold). It does not reduce RAL or DTGsusceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN95K": "Q95K is a non-polymorphic accessory mutation selected in patients receiving RAL and in vitro by EVG. Alone, it has little if any effect on INSTI susceptibility."
  },
  "Q95K,E157Q": {
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN95K": "Q95K is a non-polymorphic accessory mutation selected in patients receiving RAL and in vitro by EVG. Alone, it has little if any effect on INSTI susceptibility."
  },
  "Q95K,N155H": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN95K": "Q95K is a non-polymorphic accessory mutation selected in patients receiving RAL and in vitro by EVG. Alone, it has little if any effect on INSTI susceptibility."
  },
  "Q95K,T97A,N155H": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN95K": "Q95K is a non-polymorphic accessory mutation selected in patients receiving RAL and in vitro by EVG. Alone, it has little if any effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "Q95K,T97A,Y143C": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN95K": "Q95K is a non-polymorphic accessory mutation selected in patients receiving RAL and in vitro by EVG. Alone, it has little if any effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "Q95K,Y143R,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN95K": "Q95K is a non-polymorphic accessory mutation selected in patients receiving RAL and in vitro by EVG. Alone, it has little if any effect on INSTI susceptibility."
  },
  "R263K": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN263K": "R263K is an uncommon mutation selected in patients receiving RAL and DTG and in vitro by EVG, DTG, and BIC. It reduces EVG susceptibility by about 4-fold, and RAL, DTG, and BIC susceptibility by about 2-fold."
  },
  "S147G": {
    "IN147G": "S147G is a non-polymorphic mutation selected in patients receiving EVG. It moderately reduces EVG susceptibility (5-10-fold). It does not reduce RAL or DTGsusceptibility."
  },
  "S147G,Q148R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN147G": "S147G is a non-polymorphic mutation selected in patients receiving EVG. It moderately reduces EVG susceptibility (5-10-fold). It does not reduce RAL or DTGsusceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility."
  },
  "S153F": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN153YF": "S153Y/F are extremely rare non-polymorphic mutations selected in vitro by EVG and DTG. S153Y/F reduce RAL, DTG, and possibly BIC susceptibility about 2-fold and EVG susceptibility about 4-fold."
  },
  "S230R": {
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL, EVG, and rarely DTG. It appears to have minimal, if any, effect on INSTI susceptibility."
  },
  "T66A": {
    "IN66A": "T66A is a non-polymorphic mutation selected in patients receiving EVG and RAL, usually in combination with other INSTI-resistance mutations. It causes a moderatereduction in EVG susceptibility (~5-fold). It does not appear to reduce RAL or DTG susceptibility."
  },
  "T66A,E92Q": {
    "IN66A": "T66A is a non-polymorphic mutation selected in patients receiving EVG and RAL, usually in combination with other INSTI-resistance mutations. It causes a moderatereduction in EVG susceptibility (~5-fold). It does not appear to reduce RAL or DTG susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It causes intermediate and high-level reductions in RAL and EVG susceptibility, respectively. It is selected in vitro by DTG and reduces DTG susceptibility \u003c\u003d1.5-fold. Its effect on BIC is uncertain."
  },
  "T66A,G163R": {
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN66A": "T66A is a non-polymorphic mutation selected in patients receiving EVG and RAL, usually in combination with other INSTI-resistance mutations. It causes a moderatereduction in EVG susceptibility (~5-fold). It does not appear to reduce RAL or DTG susceptibility."
  },
  "T66I": {
    "IN66I": "T66I is a non-polymorphic mutation selected in patients receiving EVG and RAL. It reduces EVG susceptibility by about 10-fold but does not reduce RAL, DTG, or BIC susceptibility."
  },
  "T66I,T97A,G163R": {
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN66I": "T66I is a non-polymorphic mutation selected in patients receiving EVG and RAL. It reduces EVG susceptibility by about 10-fold but does not reduce RAL, DTG, or BIC susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T66I,T97A,N155H": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN66I": "T66I is a non-polymorphic mutation selected in patients receiving EVG and RAL. It reduces EVG susceptibility by about 10-fold but does not reduce RAL, DTG, or BIC susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T66I,Y143C": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN66I": "T66I is a non-polymorphic mutation selected in patients receiving EVG and RAL. It reduces EVG susceptibility by about 10-fold but does not reduce RAL, DTG, or BIC susceptibility."
  },
  "T66K": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN66K": "T66K is a non-polymorphic mutation selected in patients receiving EVG. It is associated with high-level EVG resistance, intermediate/high-level RAL resistance, and low-level DTG resistance. Its effect on BIC is not known."
  },
  "T66K,L74M,G140S,Q148R,E157Q": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN66K": "T66K is a non-polymorphic mutation selected in patients receiving EVG. It is associated with high-level EVG resistance, intermediate/high-level RAL resistance, and low-level DTG resistance. Its effect on BIC is not known.",
    "IN74MI": "L74M/I are highly polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations."
  },
  "T97A": {
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,E138A,G140S,Q148H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,E138A,Y143K": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN143KGSA": "Y143K/G/S/A are rare mutations that cause intermediate reductions in RAL susceptibility. When they occur in combination with other accessory mutations, they may also cause low-level reductions in EVG susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,E138K": {
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,E138K,E157Q": {
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,E138K,Q148R,N155H,G163K": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,E138K,S147G,N155H,E157Q": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN147G": "S147G is a non-polymorphic mutation selected in patients receiving EVG. It moderately reduces EVG susceptibility (5-10-fold). It does not reduce RAL or DTGsusceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,E157Q": {
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,E157Q,G163R": {
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,F121Y": {
    "IN121Y": "F121Y is a non-polymorphic mutation selected in vitro by RAL and EVG. It has been reported rarely in patients receiving RAL. It reduces susceptibility to RAL by ~10-fold and to EVG by ~30-fold.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,G140S,Q148H": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,G140S,Q148R,N155H,G163R": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations in patients receiving RAL or EVG. Alone, they minimally reduce susceptibility to RAL and EVG. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Alone, Q148H moderately reduces RAL and EVG susceptibility ~5 to 10-fold. Alone, Q148R/K reduce RAL and EVG susceptibility ~30 to 100-fold. However, Q148H/K/R usually occur In combination with G140S/A or E138K/A/T, in which case they reduce RAL and EVG susceptibility \u003e100-fold. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. In combination with G140S/A/C and/or E138K/A/T, they cause moderate to high level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,G163K": {
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,G163R": {
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,N155H": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,N155H,G163K": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,N155H,G163R": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,Y143C": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,Y143C,G163R,S230R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL, EVG, and rarely DTG. It appears to have minimal, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,Y143C,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,Y143C,S230R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL, EVG, and rarely DTG. It appears to have minimal, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,Y143H,N155H,E157Q": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143H": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Y143H is a less-common mutation at this position that is likely a transitional mutation between the wildtype Y amino acid and the mutant R (which differs from the wildtype Y by two nucleotides).",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,Y143H,N155H,G163R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143H": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Y143H is a less-common mutation at this position that is likely a transitional mutation between the wildtype Y amino acid and the mutant R (which differs from the wildtype Y by two nucleotides).",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,Y143R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,Y143R,G163K": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,Y143R,G163R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,Y143R,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,Y143S,S230R": {
    "IN143KGSA": "Y143K/G/S/A are rare mutations that cause intermediate reductions in RAL susceptibility. When they occur in combination with other accessory mutations, they may also cause low-level reductions in EVG susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL, EVG, and rarely DTG. It appears to have minimal, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic accessory mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. It is selected primarily by RAL and EVG. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "V151A": {
    "IN151A": "V151A is an extremely rare non-polymorphic mutation selected in vitro by an investigational INSTI. It is associated with minimally reduced susceptibility to RAL and EVG."
  },
  "V151L": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN151L": "V151L is an extemely rare non-polymorphic mutation selected in vitro by early investigational INSTIs but not in patients receiving current INSTIs. It confers intermediate / high-level reduced susceptibility to RAL and EVG and low-level reduced susceptibility to DTG."
  },
  "Y143C": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility."
  },
  "Y143C,E157Q,S230R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL, EVG, and rarely DTG. It appears to have minimal, if any, effect on INSTI susceptibility."
  },
  "Y143C,G163K,S230R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL, EVG, and rarely DTG. It appears to have minimal, if any, effect on INSTI susceptibility."
  },
  "Y143C,G163R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "Y143C,G163R,S230R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL, EVG, and rarely DTG. It appears to have minimal, if any, effect on INSTI susceptibility."
  },
  "Y143C,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility."
  },
  "Y143C,N155H,E157Q,S230R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little, if any, effect on INSTI susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL, EVG, and rarely DTG. It appears to have minimal, if any, effect on INSTI susceptibility."
  },
  "Y143C,N155H,S230R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL, EVG, and rarely DTG. It appears to have minimal, if any, effect on INSTI susceptibility."
  },
  "Y143C,S230R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL, EVG, and rarely DTG. It appears to have minimal, if any, effect on INSTI susceptibility."
  },
  "Y143H": {
    "IN143H": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Y143H is a less-common mutation at this position that is likely a transitional mutation between the wildtype Y amino acid and the mutant R (which differs from the wildtype Y by two nucleotides)."
  },
  "Y143H,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143H": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Y143H is a less-common mutation at this position that is likely a transitional mutation between the wildtype Y amino acid and the mutant R (which differs from the wildtype Y by two nucleotides).",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility."
  },
  "Y143K": {
    "IN143KGSA": "Y143K/G/S/A are rare mutations that cause intermediate reductions in RAL susceptibility. When they occur in combination with other accessory mutations, they may also cause low-level reductions in EVG susceptibility."
  },
  "Y143R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility."
  },
  "Y143R,E157Q": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little, if any, effect on INSTI susceptibility."
  },
  "Y143R,G163R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "Y143R,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations selected by RAL. Alone, Y143C and Y143R reduce RAL susceptibility ~5 and 20-fold, respectively. In combination with T97A and other accessory mutations they reduce RAL susceptibility \u003e100-fold. Alone, Y143C/R have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility (~10-fold) when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility."
  },
  "Y143S": {
    "IN143KGSA": "Y143K/G/S/A are rare mutations that cause intermediate reductions in RAL susceptibility. When they occur in combination with other accessory mutations, they may also cause low-level reductions in EVG susceptibility."
  },
  "Y143S,N155H,G163K,S230R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143KGSA": "Y143K/G/S/A are rare mutations that cause intermediate reductions in RAL susceptibility. When they occur in combination with other accessory mutations, they may also cause low-level reductions in EVG susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It reduces RAL and EVG susceptibility \u003e15-fold. It causes minimal if any clinically significant reduction in DTG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are commonly selected in patients receiving RAL and possibly EVG. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL, EVG, and rarely DTG. It appears to have minimal, if any, effect on INSTI susceptibility."
  },
  "Y143S,S230R": {
    "IN143KGSA": "Y143K/G/S/A are rare mutations that cause intermediate reductions in RAL susceptibility. When they occur in combination with other accessory mutations, they may also cause low-level reductions in EVG susceptibility.",
    "IN230R": "S230R is a non-polymorphic accessory mutation selected by RAL, EVG, and rarely DTG. It appears to have minimal, if any, effect on INSTI susceptibility."
  }
}